Business Update16 Oct 2026, 02:56 pm
Venus Remedies Secures 5 Marketing Authorisations in 4 Countries
AI Summary
Venus Remedies Limited has obtained five crucial marketing authorisations across Kazakhstan, Peru, Kuwait, and Argentina. These approvals will expand the company's pharmaceutical portfolio, including Vancomycin, Fluorouracil, Fulvestrant, Methotrexate, and Meropenem, in key global markets spanning the CIS region, Latin America, and the Middle East. This strategic move reinforces Venus Remedies' commitment to global market expansion and making quality pharmaceutical solutions more accessible worldwide. The company, a leader in critical-care injectables, already has a presence in over 100 countries.
Key Highlights
- Secured five marketing authorisations in Kazakhstan, Peru, Kuwait, and Argentina.
- Expands access to key drugs like Vancomycin, Fluorouracil, Fulvestrant, Methotrexate, Meropenem.
- Strengthens international presence in CIS, Latin America, and Middle East markets.
- Reinforces focus on global portfolio expansion and market accessibility.
- Company has an existing footprint in over 100 countries.
Price Impact
More from VENUSREM